Gapping up
In reaction to strong earnings/guidance: PERY +3.3%, JRJC +2.8%, OZRK+0.5%
M&A news: MRO +2.3% (to sell certain non-core assets for $950 mln)
Select EU financial related names showing continued strength: SAN +2.1%,ING +1.8%, BCS +1.5%, CS +1.2%, DB +0.6%
Select metals/mining stocks trading higher: BHP +3.9%, RIO +3.8%, BBL+3.4%, MTL +3.1%, VALE +2.5%, FCX +2.2%
Select oil/gas related names showing strength: REXX +11.2%, LEI +5.3%, HLX+4.7%, SDRL +3.9%, CHK +3.6%, RIG +1.6%, PBR +1%, STO +0.8%
Other news: EGLE +14.3% (Goldentree Asset Management disclosed active 18.6% stake in 13D), ARNA +10.3% (reports favorable results from Phase 1b multiple-ascending dose clinical trial of APD371), SUNE +7% (continued volatility in pre-mkt action), NMR +4.6% (confirms strategic changes in EMEA and the Americas), CEL +3% (announces Israeli Antitrust & Ministry of Communications oppose Golan Telecom purchase), VRX +1% (completes amendment to its credit facility to extend the deadline for filing its 10-K to May 31)
Analyst comments: FOLD +8.1% (target raised to $15 at Chardan Capital Markets; feels co could be bought for >$22.50/share), CPXX +6% (initiated with a Buy at Needham), P +3.2% (initiated with a Buy at Citigroup), MT+2.8% (upgraded to Buy from Neutral at Goldman; added to Conviction Buy List), YNDX +2.5% (upgraded to Buy from Neutral at Goldman), N +2.4% (initiated with an Overweight at Mitsubishi UFJ), GLW +2.1% (upgraded to Buy from Neutral at Goldman)
In reaction to strong earnings/guidance: PERY +3.3%, JRJC +2.8%, OZRK+0.5%
M&A news: MRO +2.3% (to sell certain non-core assets for $950 mln)
Select EU financial related names showing continued strength: SAN +2.1%,ING +1.8%, BCS +1.5%, CS +1.2%, DB +0.6%
Select metals/mining stocks trading higher: BHP +3.9%, RIO +3.8%, BBL+3.4%, MTL +3.1%, VALE +2.5%, FCX +2.2%
Select oil/gas related names showing strength: REXX +11.2%, LEI +5.3%, HLX+4.7%, SDRL +3.9%, CHK +3.6%, RIG +1.6%, PBR +1%, STO +0.8%
Other news: EGLE +14.3% (Goldentree Asset Management disclosed active 18.6% stake in 13D), ARNA +10.3% (reports favorable results from Phase 1b multiple-ascending dose clinical trial of APD371), SUNE +7% (continued volatility in pre-mkt action), NMR +4.6% (confirms strategic changes in EMEA and the Americas), CEL +3% (announces Israeli Antitrust & Ministry of Communications oppose Golan Telecom purchase), VRX +1% (completes amendment to its credit facility to extend the deadline for filing its 10-K to May 31)
Analyst comments: FOLD +8.1% (target raised to $15 at Chardan Capital Markets; feels co could be bought for >$22.50/share), CPXX +6% (initiated with a Buy at Needham), P +3.2% (initiated with a Buy at Citigroup), MT+2.8% (upgraded to Buy from Neutral at Goldman; added to Conviction Buy List), YNDX +2.5% (upgraded to Buy from Neutral at Goldman), N +2.4% (initiated with an Overweight at Mitsubishi UFJ), GLW +2.1% (upgraded to Buy from Neutral at Goldman)